May 10, 2018 10:15 AM EDT

Astellas signs Asian licensing deal with Aquinox; Aravive touts early-stage PoC

Brittany Meiling

→ Tokyo’s Astellas Pharma has inked a licensing deal with Vancouver’s Aquinox Pharmaceutical, snagging development and commercialization rights for Aquinox’s lead drug candidate rosiptor in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Astellas signs Asian licensing deal with Aquinox; Aravive touts early-stage PoC

Brittany Meiling

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Astel­las signs Asian li­cens­ing deal with Aquinox; Ar­a­vive touts ear­ly-stage PoC

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Astellas signs Asian licensing deal with Aquinox; Aravive touts early-stage PoC